Voyager Therapeutics, Inc. — Q1 2024 Form 10-Q
Reporting period: Three months ended March 31, 2024. Voyager is a clinical-stage biotechnology company developing genetic medicines and antibodies for neurological diseases. It has no product sales; revenue is primarily from collaborations and licenses.
Financial performance and position
Amounts below are in millions of dollars unless noted.
| Metric | Q1 2024 | Q1 2023 / comparison |
|---|---|---|
| Collaboration revenue | $19.5 | $150.5; down $131.0 |
| Research and development expense | $27.1 | $18.6; up $8.5 |
| General and administrative expense | $8.6 | $9.0; down $0.4 |
| Operating loss / income | $(16.2) | $122.9 income |
| Interest income | $4.9 | $1.9 |
| Net loss / income | $(11.3), or $(0.20) per share | $124.0 income, or $3.05 basic per share |
| Cash from operating activities | $58.8 provided | $123.6 provided |
The prior-year quarter included substantial, non-recurring collaboration revenue from Novartis option exercises and delivery of a Neurocrine license. Q1 2024 revenue included $11.5 million from the 2023 Neurocrine agreement, $6.5 million from the 2019 Neurocrine agreement, $0.8 million from Novartis collaboration activity, and $0.7 million related to Novartis stock issuance. Q1 revenue also included a $7.3 million favorable revision to estimated Neurocrine research services and a $4.4 million cumulative revenue catch-up after a $5.0 million Friedreich’s ataxia milestone became payable.
R&D expense growth reflected higher program staffing, external research/manufacturing and IND-enabling work, and added facility costs. The increase in interest income reflected higher invested balances and rates. Operating cash flow benefited from collection of an approximately $80 million Novartis upfront payment receivable; it should not be read as recurring operating cash generation.
At March 31, 2024, cash and cash equivalents were $143.1 million and marketable securities were approximately $257.5 million, for total cash, cash equivalents and marketable securities of $400.5 million. Current assets were $409.1 million and current liabilities $72.6 million. Total liabilities were $128.7 million, including deferred revenue and lease liabilities; the filing reports no conventional debt balance. Accumulated deficit was $272.5 million.
Financing included $93.5 million net proceeds from a January public offering and approximately $19.3 million from Novartis’s stock purchase. Common shares outstanding rose from 44.0 million at year-end to 54.3 million at March 31; the offering also issued 3.33 million pre-funded warrants, exercisable at $0.001 per share subject to ownership limits.
Business developments, outlook and risks
- Pipeline: FDA cleared the IND for wholly owned anti-tau antibody VY-TAU01 in March. Voyager expected to dose the first healthy volunteer in a Phase 1a trial in the coming weeks, initiate a Phase 1b trial in early Alzheimer’s patients in 2025, and potentially report initial tau PET data in 2026. It expects an IND for SOD1 ALS gene therapy VY9323 in mid-2025 and for its tau-silencing gene therapy in 2026.
- Collaborations: Neurocrine selected a Friedreich’s ataxia development candidate in February, triggering a $5.0 million payment received in Q1; the program is expected to enter first-in-human trials in 2025. Neurocrine selected a GBA1 candidate in April, triggering a $3.0 million payment expected in Q2 2024; Voyager expects an IND filing in 2025. Novartis collaboration programs for spinal muscular atrophy and Huntington’s disease remain in development.
- Cash outlook: Management said existing resources, together with anticipated collaboration reimbursements, near-term milestones and interest income, are expected to fund planned operating and capital needs into 2027. A note to the financial statements separately says current resources are sufficient for at least twelve months from issuance. The longer runway depends on the stated expected inflows and operating assumptions, not product revenue.
- Spending and funding: Voyager expects expenses to rise as it advances programs and begins clinical development. It may need substantial additional funding; financing may be unavailable or dilutive, and collaboration or licensing transactions could require surrendering valuable rights. Development costs and timelines are uncertain, and candidates may fail to obtain approval or commercial success.
- Other items: The company took control of additional Lexington laboratory and office space in February, recording a $26.7 million right-of-use asset and lease liability; its leases extend through 2031 at that location. Marketable securities had $230.7 million in an unrealized loss position, which management attributed to interest-rate changes rather than credit losses. No material litigation was pending, and no off-balance-sheet arrangements were reported. Management found disclosure controls effective as of quarter-end.
Important facts for investors to verify
- Timing and execution of VY-TAU01’s first clinical dosing and the stated 2025–2026 development milestones.
- Whether collaboration reimbursements, milestone receipts and interest income support management’s runway estimate into 2027.
- How much future revenue depends on collaboration accounting estimates, catch-up adjustments and milestone achievements rather than recurring product sales.
- Potential dilution from pre-funded warrants, equity awards and future capital raises.
- Lease obligations and rising R&D costs as additional programs move toward clinical testing.